Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- Check6 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.3%
- Check13 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.5%
- Check20 days agoChange DetectedDifference0.1%
- Check27 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.3%
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check42 days agoChange DetectedThe web page has been updated to reflect a new study with 71 locations, including several new sites in the United States and China, and the results have been posted. Additionally, the maximum tolerated dose and recommended phase 2 dose of pralsetinib have been defined, along with various metrics related to participant responses and adverse events.SummaryDifference100%
Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.